Clinical trial · Observational
Retrospective WGS Study
Assessing the Clinical Benefits of Whole Genome Sequencing for Children With Neoplasms
NCT06820294CI-TRIAL-00085801enrolling by invitationClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This retrospective case series reviews clinical notes to assess whether NHS whole genome sequencing provides tangible benefits for paediatric tumours.
Conditions
Conditions (3)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer | Malignant Neoplasm | ALIAS | 0.90 |
| Neoplasm | Neoplasm | ONTOLOGY_EXACT | 0.90 |
| Pediatric Cancer | Childhood Malignant Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| No intervention | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- All children/young people (up to 21years) diagnosed with neoplastic disorder who have had NHSE WGS
- description
- All children and young people (up to the age of 21 years) diagnosed with a neoplastic disorder who have been offered NHSE whole genome sequencing.
- interventionNames
- Other: No intervention
Primary outcomes (1)
- measure
- The proportion of children clinically benefiting from whole genome sequencing
- timeFrame
- 5.5 years
- description
- The proportion of children clinically benefiting from whole genome sequencing in terms of improving diagnoses, treatment, and prognostication, amongst other aspects
Secondary outcomes (1)
- measure
- Relation between mutation data and disease phenotypes
- timeFrame
- 5.5 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 0 Years
- Maximum age
- 21 Years
Show eligibility criteria text
Inclusion Criteria: * All children and young people (up to the age of 21 years) diagnosed with a neoplastic disorder who have been offered NHSE whole genome sequencing. Exclusion Criteria: * Anyone not offered NHSE whole genome sequencing * Individuals beyond the age of 21 * Individuals without a neoplastic disorder.
References
Publications (0)
Data not yet available
No reference posted for this study.